If we go back further, the stock has jumped 3664.58 per cent in the last five years. Meanwhile, the stock has witnessed a correction of 7% in the last one week and has dipped by 18% in the last ...
Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback